The company's GIP/GLP-1 agonist, VK2735, appears undifferentiated, facing intense competition from existing and emerging obesity treatments. Plans to launch VK2735 with an auto-injector could ...
Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid increasing demand for GLP-1 therapy. Viking Therapeutics has signed a long-term ...
H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...
Obesity upstart Viking Therapeutics has agreed to pay a total of $150 million through 2028 to enlist CordenPharma for production of its dual GIP/GLP-1 agonist VK2735. Under the deal, CordenPharma ...
The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.
Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment ...
The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback